A Great Fiducial Marker That Helps Improve Radiotherapy
New! Gold Anchor MR+ for exceptional MRI visibility
Minimally invasive
Industry leading thin needles
Great Visibility
Easily register kV, CT and MR images
Instant Stability
Multiple cut-outs allow the marker to fold
A fiducial marker made in Sweden
The Gold Anchor has been invented and developed by Ingemar Naslund, M.D, Associate Professor, working as head of the Division of Radiation Therapy, Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden for 20 years, where he was one of the inventors of the SBRT technique in 1991 together with Ingmar Lax and Henric Blomgren.
Safe to use in almost any inner organ
- Prostate
- Liver
- Pancreas
- Kidney
- Adrenal gland
- Lung
- Cervix and other gynecologic organs
- Oligomets in abdomen
- Inguinal metastases
- Head & neck
- Etc.
Ideal for Intrafraction Motion Management
Gold Anchor fiducial markers in prostate, automatically detected by Varian TrueBeam®
Images courtesy of the Sahlgrenska University Hospital
Varian’s Advanced IGRT & Motion package includes the Auto Beam Hold (ABH) feature. ABH is an imaging technique that monitors the patient during radiation treatments.
This is achieved by detecting implanted fiducial markers in radiographic images acquired during treatment. The treatment beam is paused when ABH observes a discrepancy between the planned markers positions and the detected positions.
Enabling state of the art radiotherapy
- Intrafraction Motion Management
- Onboard kV-imaging
- Elekta XVI seed match
- Varian TrueBeam Auto-Beam-Hold
- Proton Therapy
- Synchrony CyberKnife & Radixact
- Brainlab ExacTrac Dynamic
- Frameless SBRT
- Tomotherapy
- CT/MRI fusion
Financially beneficial
Fiducial marker based IGRT vs. CBCT (without markers)
- Faster, safer and easier positioning using either orthogonal 2D images or marker detection software on kV/CBCT.
- Enabling tracking of intrafraction motion.
- Providing confidence to hypofractionate.
Gold Anchor vs. traditional fiducial markers
- Reduced complications from implantation.
- Less costly to implant percutaneously than endoscopically.
- Shorter lead times.